Sotatercept denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sotatercept on Medical-Necessity Grounds

Sotatercept (Winrevair) is an activin signaling inhibitor approved by the FDA for pulmonary arterial hypertension (PAH). UHC's medical-necessity denials for sotatercept typically arise because the reviewer has determined that the clinical documentation does not clearly establish that the patient meets every criterion in UHC's published coverage policy — which may include diagnostic confirmation of PAH, documentation of functional class, prior treatment history, and specialist involvement. These denials are almost always worth challenging because PAH is a serious, progressive condition and the administrative record often supports medical necessity more strongly than the initial submission reflected.

## Your Appeal Rights

You have layered federal protections:

• ERISA §503 (if employer-sponsored plan): Requires a full-and-fair review of your internal appeal. UHC must review all submitted evidence, including any new records you provide.
• ACA §2719 external review: After exhausting internal appeals, you may request an independent external review by an accredited Independent Review Organization (IRO). The external reviewer is not bound by UHC's internal criteria and must apply generally accepted medical standards. You typically have approximately four months from the denial notice to file for external review — confirm the exact deadline on your Explanation of Benefits.
• Expedited review: If your condition is urgent, request an expedited internal appeal and expedited external review simultaneously. PAH's progressive nature commonly justifies expedited processing.

## Documentation to Gather

Assemble the following before filing your appeal:

1. Diagnosis confirmation: Right-heart catheterization report confirming PAH diagnosis and hemodynamic measurements; echocardiography reports; pulmonary function tests. 2. Functional severity: Most recent 6-minute walk distance test or other functional-class assessment documented in the chart. 3. Prior treatment history: Dated records showing which PAH-approved therapies were tried, for how long, and what the clinical response or reason for inadequacy was. 4. Specialist involvement: Letter from a board-certified pulmonologist or PAH specialist attesting to the medical necessity of sotatercept specifically and why it is appropriate for this patient. 5. Prescriber medical-necessity letter: A detailed letter tying each of UHC's stated criteria directly to chart documentation.

## Criteria-Mapping Structure

This is the single most effective appeal tool. Obtain UHC's current published medical/coverage policy for sotatercept. Copy each listed requirement verbatim into a table, then fill the second column with the exact chart fact that satisfies it — the date, test result, or clinical finding. If any criterion is ambiguous or not addressed in the chart, request an addendum from the treating physician before submission. Reviewers and external IRO panelists respond strongly to explicit, one-for-one criterion mapping.

## Next Step

Request the complete claim file and UHC's written denial reason under ERISA §503(g) or your state's insurance regulations. The denial letter must cite the specific clinical criteria not met — use that language as the exact framework for your rebuttal.